Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Fibulin-1 is required for bone formation and Bmp-2-mediated induction of Osterix.

Bone | 2014

The extracellular matrix protein Fibulin-1 (Fbln1) has been shown to be involved in numerous processes including cardiovascular and lung development. Here we have examined the role of Fbln1 in bone formation. Alizarin red staining of skulls from Fbln1-deficient mice showed reduced mineralization of both membranous and endochondral bones. MicroCT (μCT) analysis of the calvarial bones (i.e., frontal, parietal and interparietal bones collectively) indicated that bone volume in Fbln1 nulls at neonatal stage P0 were reduced by 22% (p=0.015). Similarly, Fbln1 null frontal bones showed a 16% (p=0.035) decrease in bone volume, with a reduction in the interfrontal bone, and a discontinuity in the leading edge of the frontal bone. To determine whether Fbln1 played a role in osteoblast differentiation during bone formation, qPCR was used to measure the effects of Fbln1 deficiency on the expression of Osterix (Osx), a transcription factor essential for osteoblast differentiation. This analysis demonstrated that Osx mRNA was significantly reduced in Fbln1-deficient calvarial bones at developmental stages E16.5 (p=0.049) and E17.5 (p=0.022). Furthermore, the ability of Bmp-2 to induce Osx expression was significantly diminished in Fbln1-deficient mouse embryo fibroblasts. Together, these findings indicate that Fbln1 is a new positive modulator of the formation of membranous bone and endochondral bone in the skull, acting as a positive regulator of Bmp signaling.

Pubmed ID: 25201465 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCRR NIH HHS, United States
    Id: 5P20RR017696
  • Agency: NIA NIH HHS, United States
    Id: R21 AG043718
  • Agency: NIGMS NIH HHS, United States
    Id: P20 GM103499
  • Agency: NIGMS NIH HHS, United States
    Id: P30 GM103342
  • Agency: NCRR NIH HHS, United States
    Id: C06 RR015455
  • Agency: NHLBI NIH HHS, United States
    Id: R01HL095067
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL095067
  • Agency: NCRR NIH HHS, United States
    Id: P20 RR017696
  • Agency: NIGMS NIH HHS, United States
    Id: P30 GM103331
  • Agency: NIA NIH HHS, United States
    Id: 5R21AG043718
  • Agency: NIGMS NIH HHS, United States
    Id: P30GM10331

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NanoStriDE (tool)

RRID:SCR_003407

Web application that accepts the raw count data produced by the NanoString nCounter analysis system, normalizes it according to guidelines provided by NanoString Technologies, performs differential expression analysis on the normalized data, and provides a heatmap of the results from the differential expression analysis.

View all literature mentions